Gastrointestinal Infection Testing Market Forecasted to Grow at a 5.2% CAGR by 2032 | Persistence Market Research

Overview of the Gastrointestinal Infection Testing Market

The gastrointestinal infection testing market has shown significant growth over the past few years and is projected to continue its upward trajectory in the coming years. The global market size was valued at approximately USD 467.2 million in 2025 and is expected to grow at a compound annual growth rate (CAGR) of 5.2% from 2025 to 2032, reaching a value of USD 617.7 million by 2032. Several factors, including the rising prevalence of foodborne illnesses, advances in diagnostic technologies, and the increasing demand for rapid and accurate diagnostic solutions, are driving market expansion.

Foodborne pathogens such as Salmonella, Escherichia coli (E. coli), and Campylobacter are some of the major contributors to gastrointestinal infections, leading to a surge in diagnostic testing. According to the World Health Organization (WHO), foodborne diseases result in 600 million illnesses and 420,000 deaths globally every year. The Centers for Disease Control and Prevention (CDC) also reports that over 48 million people in the U.S. experience foodborne illnesses annually, further underscoring the demand for effective diagnostic methods. The market is experiencing significant growth due to the increasing adoption of molecular diagnostic techniques like PCR-based and next-generation sequencing (NGS) tests, which provide accurate and timely results. Point-of-care diagnostics are gaining popularity due to their ability to deliver faster results and reduce waiting times, particularly in emergency settings.

Get a Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response): https://www.persistencemarketresearch.com/samples/17314

Key Growth Drivers and Leading Segments

Several key drivers are fueling the growth of the gastrointestinal infection testing market. The growing demand for rapid and non-invasive diagnostic solutions is at the forefront of this expansion. Innovations in diagnostic technologies, particularly in molecular diagnostics and automated platforms, are helping to identify pathogens with higher precision and speed. These technologies are also making it easier to conduct tests in remote and low-resource settings, broadening their accessibility.

The instrument segment is projected to dominate the market with a market share of 60% by 2025. This growth is primarily driven by the need for accurate diagnostics, which is leading to increased demand for sophisticated instruments like PCR machines, immunoassay analyzers, and culture-based diagnostic tools. North America is expected to lead the gastrointestinal infection testing market, accounting for a 35% share by 2025. The region's well-established healthcare infrastructure, high healthcare spending, and the widespread adoption of advanced diagnostic technologies contribute to this market dominance.

Key Highlights from the Report

• The global gastrointestinal infection testing market is projected to reach USD 617.7 million by 2032, growing at a CAGR of 5.2%.
• The increasing prevalence of foodborne illnesses is one of the primary drivers of market growth.
• Point-of-care diagnostics are gaining traction due to their ability to deliver quick results in emergency situations.
• The molecular diagnostic tests segment is expected to account for 30% of the market share by 2025, driven by rapid testing demand.
• North America is projected to dominate the market with a 35% market share in 2025.
• The instruments segment is anticipated to capture the largest share of the market, driven by the need for accurate diagnostic tools.

Market Segmentation

The gastrointestinal infection testing market is segmented across various categories, including product type, test type, and infection type. By product type, the market is primarily divided into instruments and reagents. Instruments, which include PCR machines, immunoassay analyzers, and culture-based tools, are expected to hold a significant share of the market due to their capability for accurate and rapid diagnostics. The reagents segment is expected to grow alongside, owing to their critical role in enabling molecular diagnostic tests like PCR-based testing.

By test type, molecular diagnostics is a rapidly growing segment. This includes techniques like Polymerase Chain Reaction (PCR) and Next-Generation Sequencing (NGS), which offer enhanced sensitivity and specificity for pathogen detection. These tests allow for the detection of pathogens in a fraction of the time compared to traditional culture-based tests, making them ideal for clinical and emergency settings. As more laboratories adopt these technologies, the market for molecular diagnostic tests is expected to witness significant growth.

Regional Insights

In terms of geographical insights, North America is expected to dominate the gastrointestinal infection testing market, contributing to a substantial share of 35% by 2025. This is due to the high prevalence of gastrointestinal infections, supported by the robust healthcare infrastructure and adoption of advanced diagnostic technologies. The region's healthcare system, characterized by its technological advancements and access to resources, plays a key role in facilitating the growth of this market segment.

Europe follows closely behind in market size and is expected to experience steady growth due to the increasing focus on public health campaigns and the growing demand for non-invasive diagnostic methods. The region's healthcare system is also witnessing an uptick in the adoption of molecular diagnostic tests, further driving the demand for accurate and efficient testing solutions.

Market Drivers

Several key factors are driving the growth of the gastrointestinal infection testing market. The most notable of these is the increasing prevalence of gastrointestinal infections worldwide, particularly foodborne illnesses, which have spurred a greater need for diagnostic testing. The WHO estimates that foodborne diseases cause 600 million illnesses annually, a statistic that has heightened the focus on timely and accurate diagnostics.

Additionally, the rise of molecular diagnostic technologies has significantly improved the accuracy and speed of pathogen detection, especially in emergency situations. Techniques like PCR and NGS offer high sensitivity and specificity, enabling the rapid identification of pathogens at low concentrations. These advancements have made it possible for healthcare providers to deliver quicker treatment, improving patient outcomes and reducing healthcare burdens.

Market Restraints

Despite the favorable growth prospects, the gastrointestinal infection testing market faces several challenges. One of the major restraints is the inadequate diagnostic infrastructure in developing regions. Many healthcare facilities in low-income countries lack the necessary resources, including trained personnel and advanced diagnostic tools, to conduct molecular tests effectively. According to WHO, about 40% of healthcare facilities in low-income countries lack basic diagnostic tools for infectious diseases, which hinders the widespread adoption of new diagnostic technologies.

Furthermore, the cost of advanced diagnostic tests can be prohibitive, especially for smaller healthcare facilities and in developing countries where healthcare budgets are constrained. This limits access to high-quality testing solutions, particularly in areas where gastrointestinal infections are most prevalent.

Market Opportunities

The gastrointestinal infection testing market presents several growth opportunities, particularly in the innovation of diagnostic technologies. Emerging technologies such as microfluidic platforms and syndromic testing panels hold great promise for improving diagnostic efficiency. Syndromic panels, which can detect multiple pathogens in a single test, are especially valuable in cases where symptoms overlap between various gastrointestinal infections. This technology can streamline diagnostics, reduce testing time, and ultimately enhance patient care.

Another key opportunity lies in the growing demand for non-invasive diagnostic methods, such as breath tests and fecal tests. These options offer greater comfort to patients and are easier to administer, making them more appealing in both clinical and home settings. Additionally, advancements in personalized medicine are opening up new avenues for gastrointestinal infection testing by offering treatments tailored to individual patient needs based on their specific genetic profiles.

Reasons to Buy the Report

✔ Comprehensive Market Insights: Gain in-depth knowledge of the gastrointestinal infection testing market, including trends, challenges, and future growth opportunities.
✔ Detailed Forecasts: Understand the market's projected growth from 2025 to 2032, helping in long-term planning.
✔ Key Segmentation Analysis: Learn about various market segments, including product type, test type, and geographical regions.
✔ Competitive Intelligence: Stay ahead of competitors by understanding the strategies and innovations of key players in the market.
✔ Actionable Strategies: Use the insights to develop strategies for market entry or expansion, particularly in high-growth regions like North America.

Company Insights

Key players in the gastrointestinal infection testing market include:

• Bio-Rad Laboratories, Inc.
• Thermo Fisher Scientific, Inc.
• Abbott Laboratories
• F. Hoffmann-La Roche AG
• Cepheid (a Danaher company)
• DiaSorin S.p.A.
• bioMérieux SA
• Quidel Corporation
• Hologic, Inc.

Recent Developments

• In August 2024, MP Biomedicals introduced a new series of in vitro diagnostic tests utilizing immunochromatographic technology to detect gastrointestinal pathogens like Helicobacter pylori and Salmonella.

• In May 2024, Geneoscopy, Inc. received FDA approval for its noninvasive colorectal cancer screening test, ColoSense, marking a significant development in gastrointestinal diagnostic technology.

This comprehensive understanding of the gastrointestinal infection testing market offers valuable insights for stakeholders, providing an overview of its dynamics, opportunities, and challenges.

About Persistence Market Research:

At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.

Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.

Contact Us:

Persistence Market Research
G04 Golden Mile House, Clayponds Lane
Brentford, London, TW8 0GU UK
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web: https://www.persistencemarketresearch.com

This release was published on openPR.